The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2020

Filed:

Jun. 16, 2016
Applicants:

The Jackson Laboratory, Bar Harbor, ME (US);

University of Massachusetts, Boston, MA (US);

Inventors:

Leonard D. Shultz, Bar Harbor, ME (US);

Mohit Kumar Verma, Brewer, ME (US);

Dale L. Greiner, Hubbardston, MA (US);

Michael A. Brehm, Dudley, MA (US);

Assignees:

The Jackson Laboratory, Bar Harbor, ME (US);

University of Massachusetts, Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); A61K 49/00 (2006.01); C12N 15/90 (2006.01); C07K 14/47 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0275 (2013.01); A01K 67/027 (2013.01); A01K 67/0271 (2013.01); A61K 49/0008 (2013.01); C07K 14/472 (2013.01); C12N 15/907 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/07 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0387 (2013.01);
Abstract

The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/BIN, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-PrkdcIL2rg/SzJ (NSG), NOD.Cg-Rag1IL2rg/SzJ (NRG) and NOD.Cg-PrkdcIL2rg/JicTAc (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice. Methods for assessment of therapeutic antibodies or putative therapeutic antibodies in the genetically modified immunodeficient mice characterized by an intact complement system are provided according to specific aspects of the present invention.


Find Patent Forward Citations

Loading…